Apatinib mesylate is under clinical development by Elevar Therapeutics and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According to GlobalData, Phase II drugs for Gastroesophageal (GE) Junction Carcinomas have a 28% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Apatinib mesylate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Apatinib mesylate overview
Apatinib Mesylate (Aitan) is an anti-neoplastic agent. It is formulated as film-coated tablets for oral route of administration. Apatinib is indicated in treatment for metastatic gastric cancer and hepatocellular carcinoma.
Apatinib (YN968D1) is under development for the treatment of advanced right-sided colon cancer, retroperitoneal sarcomas, osteosarcoma, liver metastasis of gastrointestinal pancreatic neuroendocrine tumor (GEP-NET), neuroendocrine tumors, metastatic pancreatic cancer, metastatic hepatocellular carcinoma, her-2 negative, HR-positive progressive breast cancer, metastatic gastric cancer, adenocarcinoma of gastroesophageal junction, relapsed/refractory non-squamous non-small cell lung cancer (NSCLC), metastatic colorectal cancer, gestational trophoblastic neoplasia(GTN), intrahepatic cholangiocarcinoma, small-cell lung cancer, metastatic triple-negative breast cancer, progressive/metastatic refractory thyroid cancer, epithelial ovarian cancer, esophageal squamous cell carcinoma, metastatic head and neck squamous cell carcinoma, metastatic esophageal squamous cell carcinoma, recurrent cervical cancer, endometrial cancer, relapsed or refractory extranodal nasal type NK/T cell lymphoma, peripheral T-cell lymphoma, angioimmunoblastic T-cell lymphoma and anaplastic large cell lymphoma, gallbladder cancer, thymic epithelial tumor, recurrent high-grade glioma, papillary thyroid cancer, medullary thyroid cancer, follicular thyroid cancer, recurrent glioblastoma multiforme, advanced lung adenocarcinoma, advanced malignant melanoma, urothelial carcinoma, peritoneal cancer, fallopian tube cancer renal cell carcinoma and primary pulmonary lymphoepithelioid carcinoma, synovial sarcoma, leiomyosarcoma, angiosarcoma, undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma, liposarcoma, fibrosarcoma, clear cell sarcoma, epithelioid sarcoma, malignant peripheral nerve sheath tumor, undifferentiated sarcoma, rhabdomyosarcoma, dermatofibrosarcoma protuberans, Ewing’s sarcoma /primary neural ectoderm tumors, desmoplastic small round cell tumor, inflammatory myofibroblastic sarcoma, malignant solitary fibroma, gastroesophageal (GE) junction carcinomas and radiation-induced brain injury. It was also under development for the treatment of metastatic advanced biliary tract carcinoma, gastrointestinal stromal tumor (GIST), NSCLC, triple negative breast cancer, colorectal cancer, soft tissue sarcoma, metastatic adenoid cystic carcinoma, and non-metastatic nasopharyngeal carcinoma (NPC).
Elevar Therapeutics overview
Elevar Therapeutics (Elevar), is formerly known as LSK BioPartners, is a pharmaceutical company. It offers clinical development of therapies for unmet medical needs in cancer. The company develops drug candidate apatinib, a selective VEGFR-2 inhibitor for the treatment of solid tumor cancers such as metastatic gastric carcinoma, colorectal cancer, hepatocellular carcinoma, metastatic breast cancer and non-small cell lung cancer and Bruton’s tyrosine kinasefor the treatment of both hematologic and autoimmune disorders. The company has collaborations with universities, cancer institutions and medical centers. It operates in the South Korea and US. Elevar is headquartered in Fort Lee, New Jersey, the US.
For a complete picture of Apatinib mesylate’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
